Research ExplorerPublicationsLong-term follow-up of the randomised controlled trial to ev...

Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study

Standard

Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. / Fajadet, Jean; Wijns, William; Laarman, Gert-Jan; Kuck, Karl-Heinz; Ormiston, John; Baldus, Stephan; Hauptmann, Karl E; Suttorp, Maarten J; Drzewiecki, Janusz; Pieper, Michael; Schultheiss, Heinz-Peter; Mauri, Laura.

In: EUROINTERVENTION, Vol. 6, No. 5, 11.2010, p. 562-567.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fajadet, J, Wijns, W, Laarman, G-J, Kuck, K-H, Ormiston, J, Baldus, S, Hauptmann, KE, Suttorp, MJ, Drzewiecki, J, Pieper, M, Schultheiss, H-P & Mauri, L 2010, 'Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study', EUROINTERVENTION, vol. 6, no. 5, pp. 562-567. https://doi.org/10.4244/EIJV6I5A95

APA

Fajadet, J., Wijns, W., Laarman, G-J., Kuck, K-H., Ormiston, J., Baldus, S., Hauptmann, K. E., Suttorp, M. J., Drzewiecki, J., Pieper, M., Schultheiss, H-P., & Mauri, L. (2010). Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EUROINTERVENTION, 6(5), 562-567. https://doi.org/10.4244/EIJV6I5A95

Vancouver

Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, Baldus S et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EUROINTERVENTION. 2010 Nov;6(5):562-567. https://doi.org/10.4244/EIJV6I5A95

Bibtex

@article{726fa60478c84e8eae72e5c2cb74a85f,
title = "Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study",
abstract = "AIMS: We report here the final 5-year follow-up results from the ENDEAVOR II trial, which was the first randomised trial evaluating the Endeavor(tm) zotarolimus-eluting stent (ZES) compared with a bare metal stent (BMS) in patients with single, de novo coronary artery lesions.METHODS AND RESULTS: Eligible patients were randomised 1:1 to receive ZES or BMS and were followed by telephone or clinic visit up to five years. We evaluated TVF and its components (target vessel revascularisation [TVR], Q-wave or non Q-wave myocardial infarction, or cardiac death attributed to the target vessel) at five years. Additionally, we report rates of MACE, TLR, and stent thrombosis (protocol- and ARC-defined) through five years. ENDEAVOR II enrolled 1,197 patients (598 ZES, 599 BMS). At five years of follow-up, the rates of TVF (15.4% vs 24.4%), TVR (10.7% vs 20.1%), MACE (15.4% vs 24.6%), and TLR (7.5% vs 16.3%) remained significantly lower in ZES patients compared with BMS patients. ARC definite and probable very late (>1 year) stent thrombosis remained low (0.2% ZES and 0.3% BMS) through five years.CONCLUSIONS: After five years of follow-up, ZES demonstrated significantly improved clinical outcomes with sustained safety compared with BMS in patients with obstructive coronary artery disease.",
keywords = "Aged, Angioplasty, Balloon, Coronary, Coronary Artery Disease/therapy, Drug-Eluting Stents/adverse effects, Female, Follow-Up Studies, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Sirolimus/administration & dosage, Thrombosis/epidemiology, Treatment Outcome",
author = "Jean Fajadet and William Wijns and Gert-Jan Laarman and Karl-Heinz Kuck and John Ormiston and Stephan Baldus and Hauptmann, {Karl E} and Suttorp, {Maarten J} and Janusz Drzewiecki and Michael Pieper and Heinz-Peter Schultheiss and Laura Mauri",
year = "2010",
month = nov,
doi = "10.4244/EIJV6I5A95",
language = "English",
volume = "6",
pages = "562--567",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "5",

}

RIS

TY - JOUR

T1 - Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study

AU - Fajadet, Jean

AU - Wijns, William

AU - Laarman, Gert-Jan

AU - Kuck, Karl-Heinz

AU - Ormiston, John

AU - Baldus, Stephan

AU - Hauptmann, Karl E

AU - Suttorp, Maarten J

AU - Drzewiecki, Janusz

AU - Pieper, Michael

AU - Schultheiss, Heinz-Peter

AU - Mauri, Laura

PY - 2010/11

Y1 - 2010/11

N2 - AIMS: We report here the final 5-year follow-up results from the ENDEAVOR II trial, which was the first randomised trial evaluating the Endeavor(tm) zotarolimus-eluting stent (ZES) compared with a bare metal stent (BMS) in patients with single, de novo coronary artery lesions.METHODS AND RESULTS: Eligible patients were randomised 1:1 to receive ZES or BMS and were followed by telephone or clinic visit up to five years. We evaluated TVF and its components (target vessel revascularisation [TVR], Q-wave or non Q-wave myocardial infarction, or cardiac death attributed to the target vessel) at five years. Additionally, we report rates of MACE, TLR, and stent thrombosis (protocol- and ARC-defined) through five years. ENDEAVOR II enrolled 1,197 patients (598 ZES, 599 BMS). At five years of follow-up, the rates of TVF (15.4% vs 24.4%), TVR (10.7% vs 20.1%), MACE (15.4% vs 24.6%), and TLR (7.5% vs 16.3%) remained significantly lower in ZES patients compared with BMS patients. ARC definite and probable very late (>1 year) stent thrombosis remained low (0.2% ZES and 0.3% BMS) through five years.CONCLUSIONS: After five years of follow-up, ZES demonstrated significantly improved clinical outcomes with sustained safety compared with BMS in patients with obstructive coronary artery disease.

AB - AIMS: We report here the final 5-year follow-up results from the ENDEAVOR II trial, which was the first randomised trial evaluating the Endeavor(tm) zotarolimus-eluting stent (ZES) compared with a bare metal stent (BMS) in patients with single, de novo coronary artery lesions.METHODS AND RESULTS: Eligible patients were randomised 1:1 to receive ZES or BMS and were followed by telephone or clinic visit up to five years. We evaluated TVF and its components (target vessel revascularisation [TVR], Q-wave or non Q-wave myocardial infarction, or cardiac death attributed to the target vessel) at five years. Additionally, we report rates of MACE, TLR, and stent thrombosis (protocol- and ARC-defined) through five years. ENDEAVOR II enrolled 1,197 patients (598 ZES, 599 BMS). At five years of follow-up, the rates of TVF (15.4% vs 24.4%), TVR (10.7% vs 20.1%), MACE (15.4% vs 24.6%), and TLR (7.5% vs 16.3%) remained significantly lower in ZES patients compared with BMS patients. ARC definite and probable very late (>1 year) stent thrombosis remained low (0.2% ZES and 0.3% BMS) through five years.CONCLUSIONS: After five years of follow-up, ZES demonstrated significantly improved clinical outcomes with sustained safety compared with BMS in patients with obstructive coronary artery disease.

KW - Aged

KW - Angioplasty, Balloon, Coronary

KW - Coronary Artery Disease/therapy

KW - Drug-Eluting Stents/adverse effects

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Sirolimus/administration & dosage

KW - Thrombosis/epidemiology

KW - Treatment Outcome

U2 - 10.4244/EIJV6I5A95

DO - 10.4244/EIJV6I5A95

M3 - SCORING: Journal article

C2 - 21044908

VL - 6

SP - 562

EP - 567

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 5

ER -